Article
Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
The Lancet. Neurology - 1 Aug 2021
Fagan Anne M, Henson Rachel L, Li Yan, Boerwinkle Anna H, Xiong Chengjie, Bateman Randall J, Goate Alison, Ances Beau M, Doran Eric, Christian Bradley T, Lai Florence, Rosas H Diana, Schupf Nicole, Krinsky-McHale Sharon, Silverman Wayne, Lee Joseph H, Klunk William E, Handen Benjamin L, Allegri Ricardo F, Chhatwal Jasmeer P, Day Gregory S, Graff-Radford Neill R, Jucker Mathias, Levin Johannes, Martins Ralph N, Masters Colin L, Mori Hiroshi, Mummery Catherine J, Niimi Yoshiki, Ringman John M, Salloway Stephen, Schofield Peter R, Shoji Mikio, Lott Ira T
Abstract excerpt
BACKGROUND: Due to trisomy of chromosome 21 and the resultant extra copy of the amyloid precursor protein gene, nearly all adults with Down syndrome develop Alzheimer's disease pathology by the age of 40 years and are at high risk for dementia given their increased life expectancy compared with adults with Down syndrome in the past. We aimed to compare CSF biomarker patterns in Down syndrome with those of...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.